<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>Urinary Incontinence in Women – Quick Reference (Primary Care)</title>
  <style>
    :root {
      --bg: #f7f9fc;
      --card: #ffffff;
      --ink: #1f2937;         /* slate-800 */
      --muted: #5b677a;       /* slate-500 */
      --primary: #2563eb;     /* blue-600 */
      --accent: #4f46e5;      /* indigo-600 */
      --success: #15803d;     /* green-700 */
      --warning: #b45309;     /* amber-700 */
      --danger: #b91c1c;      /* red-700 */
      --border: #e5e7eb;      /* gray-200 */
      --chip: #eef2ff;        /* indigo-50 */
      --shadow: 0 10px 25px rgba(31,41,55,0.06);
      --radius-lg: 16px;
      --radius-md: 12px;
      --radius-sm: 10px;
    }

    html, body { height: 100%; }
    body {
      margin: 0;
      font-family: ui-sans-serif, system-ui, -apple-system, Segoe UI, Roboto, Ubuntu, Cantarell, Noto Sans, Helvetica Neue, Arial, "Apple Color Emoji", "Segoe UI Emoji";
      color: var(--ink);
      background: linear-gradient(180deg, var(--bg), #fff 40%);
      -webkit-font-smoothing: antialiased;
      -moz-osx-font-smoothing: grayscale;
    }

    /* Layout */
    .wrap { max-width: 1100px; margin: 0 auto; padding: 28px 20px 56px; }

    header.hero {
      background: radial-gradient(1200px 600px at 10% -20%, #e0e7ff 0%, transparent 60%),
                  radial-gradient(800px 400px at 90% 20%, #dbeafe 0%, transparent 60%);
      border: 1px solid var(--border);
      border-radius: 28px;
      padding: 28px;
      box-shadow: var(--shadow);
      display: grid; grid-template-columns: 1.1fr 0.9fr; gap: 18px; align-items: center;
    }
    @media (max-width: 920px) { header.hero { grid-template-columns: 1fr; } }

    .eyebrow { color: var(--accent); font-weight: 700; letter-spacing: .06em; text-transform: uppercase; font-size: 12px; }

    h1 { margin: 8px 0 10px; font-size: clamp(24px, 3vw, 34px); line-height: 1.15; }
    .subtitle { color: var(--muted); font-size: 15px; }

    .badge { display: inline-flex; align-items: center; gap: 8px; padding: 8px 12px; border-radius: 999px; background: var(--chip); color: #3730a3; font-weight: 600; font-size: 13px; margin-top: 12px; }
    .badge svg { width: 18px; height: 18px; }

    /* Utility */
    .grid { display: grid; gap: 18px; }
    .grid.cols-3 { grid-template-columns: repeat(3, 1fr); }
    .grid.cols-2 { grid-template-columns: repeat(2, 1fr); }
    @media (max-width: 1024px){ .grid.cols-3 { grid-template-columns: repeat(2, 1fr); } }
    @media (max-width: 720px){ .grid.cols-3, .grid.cols-2 { grid-template-columns: 1fr; } }

    .card {
      background: var(--card);
      border: 1px solid var(--border);
      border-radius: var(--radius-lg);
      box-shadow: var(--shadow);
      padding: 18px 18px 14px;
    }
    .card h2 { margin: 0 0 10px; font-size: 20px; }
    .card h3 { margin: 12px 0 8px; font-size: 16px; }
    .card p, .card li { font-size: 15px; line-height: 1.55; }

    .callout { border-left: 6px solid var(--primary); padding: 12px 14px; border-radius: var(--radius-sm); background: #eff6ff; }

    /* Color callouts */
    .danger { border-left-color: var(--danger); background: #fef2f2; }
    .success { border-left-color: var(--success); background: #ecfdf5; }
    .warning { border-left-color: var(--warning); background: #fffbeb; }

    /* Lists */
    .clean ul { margin: 8px 0 0 0; padding: 0 0 0 18px; }
    .clean li { margin: 6px 0; }

    .chip { display: inline-block; padding: 6px 10px; background: #e0f2fe; color: #075985; border: 1px solid #bae6fd; border-radius: 999px; font-size: 12px; font-weight: 700; letter-spacing: .02em; }

    /* Timeline / Flow */
    .flow { display: flex; gap: 14px; flex-wrap: wrap; }
    .step { position: relative; background: var(--card); border: 1px dashed #d1d5db; border-radius: 14px; padding: 12px 14px; flex: 1 1 260px; }
    .step strong { display: block; margin-bottom: 6px; color: var(--primary); }

    /* Icons */
    .icon { width: 18px; height: 18px; vertical-align: -3px; }

    /* Header buttons */
    .actions { display: flex; gap: 10px; flex-wrap: wrap; margin-top: 14px; }
    .btn { appearance: none; border: 1px solid var(--primary); background: var(--primary); color: #fff; padding: 10px 14px; border-radius: 12px; font-weight: 700; cursor: pointer; box-shadow: var(--shadow); }
    .btn.secondary { background: #fff; color: var(--primary); }

    /* Print */
    @media print {
      body { background: #fff; }
      header.hero, .btn { box-shadow: none !important; }
      .btn, .actions { display:none !important; }
      .wrap { padding: 0; }
      .card { break-inside: avoid; }
    }

    footer { color: var(--muted); font-size: 13px; margin-top: 18px; }
    footer a { color: var(--accent); text-decoration: none; }
  </style>
</head>
<body>
  <div class="wrap">
    <header class="hero">
      <div>
        <div class="eyebrow">Primary Care • Quick Reference</div>
        <h1>Urinary Incontinence in Women</h1>
        <p class="subtitle">Clean, rapid algorithm for assessment and management in clinic. Built from NICE CKS (last revised Jan 2025). Avoid dark‑mode; print-friendly.</p>
        <div class="badge" title="Red flags are highlighted">
          <!-- shield icon -->
          <svg class="icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><path d="M12 22s8-4 8-10V5l-8-3-8 3v7c0 6 8 10 8 10z"/></svg>
          Includes Red Flags & Quick Flow
        </div>
        <div class="actions">
          <button class="btn" onclick="window.print()">
            <!-- printer icon -->
            <svg class="icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><polyline points="6 9 6 2 18 2 18 9"></polyline><path d="M6 18H4a2 2 0 0 1-2-2v-5a2 2 0 0 1 2-2h16a2 2 0 0 1 2 2v5a2 2 0 0 1-2 2h-2"></path><rect x="6" y="14" width="12" height="8"></rect></svg>
            Print One‑Pager
          </button>
          <button class="btn secondary" onclick="window.scrollTo({top: document.body.scrollHeight, behavior: 'smooth'})">
            Jump to Summary Flow
          </button>
        </div>
      </div>
      <div class="card callout success">
        <h3 style="margin-top:0">At‑a‑Glance Types</h3>
        <div class="grid cols-2 clean">
          <div>
            <p><span class="chip">Stress UI</span> Leakage on effort/cough/sneeze.</p>
            <p><span class="chip">Urgency UI / OAB</span> Leakage with urgency ± frequency/nocturia.</p>
          </div>
          <div>
            <p><span class="chip">Mixed UI</span> Combination of stress and urgency.</p>
            <p><span class="chip">Other</span> Continuous (consider fistula/diverticulum), Overflow.</p>
          </div>
        </div>
      </div>
    </header>

    <section class="grid cols-3" style="margin-top:22px">
      <!-- Initial Assessment -->
      <article class="card">
        <h2>
          <!-- clipboard icon -->
          <svg class="icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><rect x="9" y="2" width="6" height="4" rx="1"/><path d="M9 2H7a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h10a2 2 0 0 0 2-2V4a2 2 0 0 0-2-2h-2"/></svg>
          Initial Assessment
        </h2>
        <div class="clean">
          <ul>
            <li><strong>History</strong> → classify type (Stress / Urgency(OAB) / Mixed / Other).</li>
            <li><strong>Bladder diary</strong> ≥ 3 days covering work & leisure days.</li>
            <li><strong>Urinalysis</strong> in all; culture if recurrent UTI with +leucocytes & nitrites.</li>
            <li><strong>Pelvic exam</strong> (prolapse, atrophy, diverticulum); assess pelvic floor contraction (Oxford scale).</li>
            <li><strong>Consider renal function</strong> if obstruction suspected.</li>
          </ul>
        </div>
        <div class="card callout danger" style="margin-top:12px">
          <h3 style="margin-top:0; color: var(--danger)">Red Flags – Refer</h3>
          <ul class="clean">
            <li><strong>Suspected cancer pathway (2‑week)</strong>: ≥45y with visible haematuria (unexplained or persistent post‑UTI); ≥60y with non‑visible haematuria + dysuria or raised WCC.</li>
            <li><strong>Urgent/Non‑urgent specialist</strong>: persistent bladder/urethral pain, voiding difficulty, chronic retention, palpable post‑void bladder, clinically benign pelvic mass, fecal incontinence, suspected neuro disease or urogenital fistula, prior incontinence/pelvic cancer surgery or radiation; recurrent unexplained UTIs in ≥60y (consider non‑urgent cancer referral).</li>
          </ul>
        </div>
      </article>

      <!-- Initial Management (All) -->
      <article class="card">
        <h2>
          <!-- heart icon -->
          <svg class="icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><path d="M20.8 4.6a5.5 5.5 0 0 0-7.8 0L12 5.6l-1-1a5.5 5.5 0 1 0-7.8 7.8l1 1L12 22l7.8-8.6 1-1a5.5 5.5 0 0 0 0-7.8z"/></svg>
          Initial Management (All Types)
        </h2>
        <ul class="clean">
          <li>Weight loss if <strong>BMI &gt; 30</strong>.</li>
          <li>Adjust fluids (avoid too high/low); <strong>reduce caffeine</strong>.</li>
          <li><strong>Smoking cessation</strong>.</li>
          <li>Manage reversible contributors: <em>constipation, uncontrolled diabetes</em>.</li>
          <li>Address complications: anxiety/depression, fall risk, sleep disturbance.</li>
        </ul>
        <div class="callout warning" style="margin-top:10px">
          <strong>Containment products</strong> only for temporary coping, adjunct to treatment, or long‑term after options explored; review at least annually (6‑monthly if &gt;75y).
        </div>
      </article>

      <!-- Type-specific: Stress -->
      <article class="card">
        <h2>
          <!-- activity icon -->
          <svg class="icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><path d="M9 18V5l12-2v13"/><circle cx="6" cy="18" r="3"/><circle cx="18" cy="16" r="3"/></svg>
          Stress UI – Management
        </h2>
        <ul class="clean">
          <li><strong>First‑line</strong>: ≥3 months <strong>supervised PFMT</strong> (≥8 contractions, ≥3×/day).</li>
          <li>If persistent → <strong>refer</strong> (urogyn/gynae/urology) to consider <em>colposuspension, autologous rectus fascial sling, retropubic mid‑urethral mesh sling</em> or <em>urethral bulking</em>.</li>
          <li>If surgery unsuitable/declined → <strong>duloxetine</strong> (discuss AEs; taper if stopping).</li>
        </ul>
      </article>

      <!-- Type-specific: Urgency/OAB -->
      <article class="card">
        <h2>
          <!-- droplet icon -->
          <svg class="icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><path d="M12 2.7C12 2.7 5 10 5 14.5A7 7 0 0 0 19 14.5C19 10 12 2.7 12 2.7z"/></svg>
          Urgency UI / Overactive Bladder
        </h2>
        <ul class="clean">
          <li><strong>First‑line</strong>: ≥6 weeks <strong>bladder training</strong>; continue if helpful.</li>
          <li>Consider <strong>antimuscarinic</strong> with lowest acquisition cost (e.g., oxybutynin IR, tolterodine IR, darifenacin OD). Avoid oxybutynin IR in frail older women.</li>
          <li>If contraindicated/ineffective/not tolerated → <strong>β3‑agonist</strong> (<em>mirabegron</em> or <em>vibegron</em> per local formulary).</li>
          <li>Other oral options (if switching/adjusting): fesoterodine, oxybutynin ER or transdermal, propiverine (IR/ER), solifenacin, tolterodine ER, trospium (IR/ER).</li>
          <li><em>Do not offer</em>: flavoxate, propantheline, imipramine.</li>
          <li><strong>If refractory</strong> or patient prefers → specialist referral (botulinum toxin A, sacral neuromodulation, augmentation cystoplasty, urinary diversion).</li>
        </ul>
        <div class="callout" style="margin-top:10px">
          <strong>Adjuncts:</strong> topical vaginal oestrogen for atrophy; desmopressin for troublesome nocturia in carefully selected women.
        </div>
      </article>

      <!-- Type-specific: Mixed -->
      <article class="card">
        <h2>
          <!-- shuffle icon -->
          <svg class="icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><path d="M16 3h5v5"/><path d="M4 20l7-7 4-4"/><path d="M21 3l-7 7"/><path d="M21 16v5h-5"/><path d="M15 21l6-6"/></svg>
          Mixed UI – Management
        </h2>
        <p>Treat the <strong>predominant symptom</strong>:</p>
        <ul class="clean">
          <li><strong>Predominant stress</strong> → follow Stress UI pathway before surgery; consider OAB meds if needed.</li>
          <li><strong>Predominant urgency</strong> → follow Urgency/OAB pathway.</li>
        </ul>
      </article>

      <!-- Follow-up & Monitoring -->
      <article class="card">
        <h2>
          <!-- clock icon -->
          <svg class="icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><circle cx="12" cy="12" r="10"/><path d="M12 6v6l4 2"/></svg>
          Review & Monitoring
        </h2>
        <ul class="clean">
          <li>Medicines: review ~4 weeks after start/change; then annually (6‑monthly if &gt;75y).</li>
          <li>Containment products (if long‑term): yearly review covering continence, skin integrity, changes to comorbidities/meds/BMI/mobility, and alternative options.</li>
        </ul>
      </article>

      <!-- Safety notes -->
      <article class="card">
        <h2>
          <!-- alert icon -->
          <svg class="icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><path d="M10.29 3.86L1.82 18a2 2 0 0 0 1.71 3h16.94a2 2 0 0 0 1.71-3L13.71 3.86a2 2 0 0 0-3.42 0z"/><line x1="12" y1="9" x2="12" y2="13"/><line x1="12" y1="17" x2="12" y2="17"/></svg>
          Prescribing Safety Highlights
        </h2>
        <ul class="clean">
          <li><strong>Antimuscarinics</strong>: monitor AEs (dry mouth, constipation, cognitive effects in older/frail). Avoid oxybutynin IR in older women at risk of sudden decline.</li>
          <li><strong>β3‑agonists</strong> (mirabegron/vibegron): consider hypertension/contraindications per local formulary.</li>
          <li><strong>Duloxetine</strong> for SUI if surgery unsuitable: counsel on nausea, fatigue; avoid in hepatic impairment, severe renal impairment; taper to stop.</li>
          <li><strong>Desmopressin</strong> for nocturia: fluid restriction; monitor sodium (especially ≥65y); avoid in hyponatraemia risk states.</li>
        </ul>
      </article>
    </section>

    <!-- Summary Flow -->
    <section class="card" style="margin-top:22px">
      <h2>
        <!-- map icon -->
        <svg class="icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><polygon points="1 6 1 22 8 18 16 22 23 18 23 2 16 6 8 2 1 6"/></svg>
        One‑Screen Summary Flow
      </h2>
      <div class="flow">
        <div class="step"><strong>1. Assess</strong> Classify type; UA for all; bladder diary ≥3 d; pelvic exam.</div>
        <div class="step"><strong>2. Exclude Red Flags</strong> Cancer pathway/urgent specialist as listed.</div>
        <div class="step"><strong>3. Universal</strong> Lifestyle; manage constipation/diabetes; address anxiety/falls/sleep.</div>
        <div class="step"><strong>4a. Stress UI</strong> PFMT ≥3 mo → if persistent: surgical referral ± duloxetine.</div>
        <div class="step"><strong>4b. Urgency/OAB</strong> Bladder training ≥6 wk → antimuscarinic → β3‑agonist → specialist.</div>
        <div class="step"><strong>4c. Mixed</strong> Treat predominant symptom (stress vs urgency).</div>
        <div class="step"><strong>5. Adjuncts</strong> Vaginal oestrogen for atrophy; desmopressin for selected nocturia.</div>
        <div class="step"><strong>6. Review</strong> 4‑week med review; annual long‑term review (6‑mo if &gt;75y).</div>
      </div>
    </section>

    <footer>
      Source: NICE Clinical Knowledge Summaries – <em>Incontinence: urinary, in women</em> (last revised Jan 2025). This page is a condensed reference for fast decision support; always check local formularies and full guidance for details.
    </footer>
  </div>
</body>
</html>
